



## **First US site commences clinical testing of Seracam®**

**London, UK, 8 June 2023.** Serac Imaging Systems Limited (“Serac Imaging Systems” or “the Company”), the medtech company developing a portable hybrid gamma-optical camera for medical imaging, today announces the start of clinical testing using the Seracam® camera at its first site in the United States. This is the second site to commence an investigator sponsored study comparing gamma images obtained using Seracam® with those obtained with a current state-of-the-art gamma camera for nuclear medical imaging, from the same patient on the same day.

Some of the potential applications to be explored include small organ imaging such as the thyroid, bone, renal, infection imaging, lymphatic imaging and sentinel lymph node localization. The study is expected to run for approximately six months, involving 25 patients. The study is being led by Dr Mona Natwa, chief of the Division of Molecular Imaging and Nuclear Medicine, and clinical associate professor of Radiology, at The Ohio State University Wexner Medical Centre.

**Mark Rosser, Chief Executive Officer of Serac Imaging Systems,** said:

“Commencing this study at The Ohio State University is a major step forward in the development of the camera as we expand our network of research sites. As well as generating the all-important comparison data from traditional imaging options, having hands on practical experience with the camera will enable us to further refine methods for the display and interpretation of the images. We believe that the combination of the co-aligned gamma-optical hybrid imaging capability, alongside the compact size and portability of the camera, have real potential to improve and expand nuclear imaging options, diagnosis and outcomes for patients.”

This is the second of a network of planned sites to use Seracam® in a clinical setting.

**- ENDS -**

**Seracam® is for investigational use only and has not been cleared or approved by the FDA or UK and European regulatory authorities.**

**For more information, please contact:**

Mark Rosser, Chief Executive Officer

+44 (0)20 8948 0000

[info@seraclifesciences.com](mailto:info@seraclifesciences.com)

Francetta Carr, Communications

+44 (0)7711 010 820

[francettacarr@seraclifesciences.com](mailto:francettacarr@seraclifesciences.com)

**For further details, please see:**

[www.seracimagingystems.com](http://www.seracimagingystems.com)

### **Notes to Editors**

#### **About Serac Imaging Systems**

Serac Imaging Systems Ltd is the medtech company developing a portable hybrid gamma-optical camera for medical imaging. Our lead product is Seracam® which is in development to bring the benefits of high-resolution molecular imaging to a patient’s bedside, instead of being confined for use in a hospital’s nuclear medicine imaging department. A further unique feature of this technological approach is the overlay of a gamma image

with an optical image of the same anatomical location under examination. Such portable and enhanced imaging technology has the potential to help clinicians make better, more informed and more timely treatment decisions.

Seracam® is a UK and EU registered trademark.

Serac Imaging Systems Ltd is a wholly owned subsidiary of Serac Life Sciences Limited.

### **About molecular imaging**

Molecular imaging is a type of medical imaging that provides unique insights into what is happening inside the body at the cellular and molecular level helping physicians to deliver personalised medicine by delivering the right treatment to the right patient at the right time. Unlike other medical imaging technologies such as x-rays, computed tomography (CT) and ultrasound (US) which provide structural images, molecular imaging allows physicians to see how cells, tissues and organs are functioning and to measure chemical and biological processes without having to resort to biopsy or surgery.